Pirazolac - Bayer Schering Pharma/Mediolanum
Alternative Names: MY-309; SCH 376; ZK-76604Latest Information Update: 20 Sep 2024
At a glance
- Originator Bayer Schering Pharma; Mediolanum
- Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Mediolanum
- Class Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 06 Dec 2001 Discontinued-II for Rheumatic disorders in Austria (Unknown route)
- 06 Dec 2001 Discontinued-preregistration for Rheumatic disorders in Germany (Unknown route)
- 06 Dec 2001 Discontinued-preregistration for Rheumatic disorders in USA (Unknown route)